Junshi Biosciences (01877.HK): Toripalimab Receives Regular Approval from the National Medical Products Administration for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Platinum-Containing Chemotherapy

Zhito Finance APP News, Junshi Biosciences (01877.HK) announced that recently, the Company received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA), approving the toripalimab injection (trade name: Tuoyi, product code: JS001) as a monotherapy for the indication of locally advanced or metastatic urothelial carcinoma that has failed platinum-containing chemotherapy, including progression within 12 months of neoadjuvant or adjuvant chemotherapy, to be converted from conditional approval to regular approval.